Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed on Monday.

“It may be noted that some RCEP countries had tried to introduce a clause in favour of evergreening of patents, which was dropped after stiff opposition from India,” Commerce and Industry Minister Nirmala Sitharaman said in a written reply to the Lok Sabha.

The negotiations for the mega trade deal – RCEP – including intellectual property rights (IPR) chapter have not yet been finalised, she said.

“The IPR chapter of the agreement is being negotiated keeping in view our national interest as also our national legislations and various multilateral agreements on IPRs to which India is party,” she added.

Evergreening of patent right is a strategy allegedly adopted by innovators having patent rights over products to renew them by bringing in some minor changes such as adding new mixtures or formulations. It is done when their patent is about to expire.

A patent on the new form would give the innovator company a 20-year monopoly on the drug.

What is it all about?

This blog is a platform to update, share and comment on recent events concerning trade and health (Free Trade Agreements (FTAs), multilateral treaties (TRIPS and its flexibilities), IP laws and policies) as well as the question on how to create an alternative R&D system not based in IP that is guided by health needs and not profits.

If you want to contribute by writing an article, or sharing documents, pictures etc. on this topic you are highly encouraged to do so! This blog depends on your contribution! Please contact us, to get access to the page: